ReviewEye (London, England)2021
Ocular surface squamous neoplasia: management and outcomes.
Review in Eye (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Cetuximab combination with cytokine induced killer cells effectively inhibit conjunctival squamous cell carcinoma in vitro.BMC immunology · 2026Article
- Article
- Artificial Intelligence in Ocular Surface Tumors: Current Advances, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
- Case Report: Successful control of ocular surface squamous neoplasia complicated byFrontiers in medicine · 2026Article
- Case Report: Atypical ocular surface squamous cell carcinoma.Frontiers in medicine · 2026Article
- Ultrasound biomicroscopy and anterior segment OCT in ocular surface squamous neoplasia: complementary roles, case series, and targeted literature review.Frontiers in ophthalmology · 2026Article
- New Paradigm in Ocular Surface Squamous Neoplasia-Insights from a Case Report on the Use of Interferon in Treatment.Oncology research · 2026Article
- High-resolution optical coherence tomography for screening ocular surface tumors: Historical markers and future directions.World journal of clinical cases · 2025Article
- Management and outcomes of ocular surface squamous neoplasia at a tertiary hospital, South Africa.Eye (London, England) · 2025Article
- Contributions of large and agricultural animal models to immunology.Journal of immunology (Baltimore, Md. : 1950) · 2025Review
- Review
- Detection of Ocular Surface Squamous Neoplasia Using Artificial Intelligence With Anterior Segment Optical Coherence Tomography.American journal of ophthalmology · 2025Article
- Incidence, clinical features, and survival outcomes of primary malignant conjunctival tumor: a US population-based retrospective cohort analysis based on the SEER database (1975-2018).Translational cancer research · 2025Article
- Update in the Diagnosis and Management of Ocular Surface Squamous Neoplasia (OSSN).Journal of clinical medicine · 2025Review
- The critical role of primary care clinicians in the early detection of ocular surface squamous neoplasia.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2025Article
- Oncological principles in the management of ocular surface squamous neoplasia - A Review.Indian journal of ophthalmology · 2025Review
- Topical Chemotherapy for Ocular Surface Squamous Neoplasia: A Review of Adverse Effects and Their Clinical Management.Oncology research · 2025Review
- Infectious etiologies of conjunctival tumors.Expert review of ophthalmology · 2025Article
- IFNα2b/5-FU inhibits proliferation and cell cycle of squamous carcinoma cell line Cal27.International journal of ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular surface squamous neoplasia (OSSN) is the most common ocular tumour with an incidence ranging from 0.03 to 1.9 per 100,000 persons/year. The diagnosis is made on clinical suspicion and confirmed with anterior-segment optical coherence tomography (AS-OCT), cytology, or histology. The purpose of this review is to provide an overview of the management options available for OSSN and review their success and recurrence rates. Surgery is the gold standard for the management of small OSSN lesions. With the increased use of less invasive diagnostic modalities such as AS-OCT and cytology, there has been a move to use topical therapies for the management of OSSN. The most commonly used agents are interferon-α2b (IFN), mitomycin-C (MMC) and 5-fluorouracil (5FU). They have been shown to have similar resolution and recurrence rates but differ in cost and side effect profile. IFN has the lowest side effect profile, but is also the most expensive, whereas MMC has the greatest surface toxicity and is priced midway between the three. 5FU is the cheapest of the three topical agents with less surface toxicity than MMC. Radiotherapy is mostly employed as adjuvant therapy. Newer novel therapies are available but have not been widely adopted as mainstream therapy due to cost and lack of clinical evidence. OSSN has the benefit of many management options. No single modality has been shown to superior and some patients will need the use of combination therapy to achieve an optimal clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.